Please login to the form below

Not currently logged in
Email:
Password:

Levest COC promises NHS cost savings

Combined oral contraception, Levest, has won an NHS contract as the preferred drug of its type for hospitals in England

In addition to being listed by the majority of retail pharmacy wholesalers and multiples, Morningside Healthcare's combined oral contraception (COC), Levest, has won an NHS contract as the preferred drug of its type for hospitals in England.

Levest contains levenogesterel 150μg and ethinylestradiol 30μg and costs £2.55 per 63 tablets, or the equivalent of just £0.85 per cycle. This makes it 10 per cent cheaper than competitor, Microgynon 30 (ethinylestradiol and levonorgestrel), which costs £2.82 per 63 tablet, or £0.94 per cycle.

With an estimated one million women in England currently prescribed Microgynon, the potential cost savings for the NHS in England are in excess of £1m a year.

Dr Al-Azzawi, consultant gynaecologist, comments: "The clinical data demonstrates that Levest is bioequivalent to Microgynon 30 and can be prescribed in place of it without any loss of contraceptive efficacy."

5th May 2010

From: Healthcare

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...
How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....